Investors in Altimmune, Inc. Should Contact The Gross Law Firm Before October 6, 2025 to Discuss Your Rights - ALT

Core Viewpoint - Altimmune, Inc. (NASDAQ: ALT) faces a class action lawsuit following the announcement of disappointing results from its IMPACT Phase 2b MASH trial, leading to a significant drop in stock price [1]. Group 1: Company Performance - On June 26, 2025, Altimmune reported topline results from the IMPACT Phase 2b MASH trial of Pemvidutide, which failed to achieve statistical significance in the primary endpoint of fibrosis reduction [1]. - The stock price of Altimmune plummeted from $7.71 per share on June 25, 2025, to $3.61 per share on June 26, 2025, marking a decline of 53.2% in just one day [1]. Group 2: Legal Proceedings - Shareholders who purchased shares of ALT between August 10, 2023, and June 25, 2025, are encouraged to register for the class action lawsuit, with a deadline for lead plaintiff appointment set for October 6, 2025 [2]. - The Gross Law Firm is leading the class action, aiming to protect investors who suffered losses due to misleading statements from the company [3].